MDS1 and EVI1 Complex Locus Protein
"MDS1 and EVI1 Complex Locus Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA binding protein, transcriptional regulator, and proto-oncogene protein that contains 10 CYS2-HIS2 ZINC FINGERS. It functions as a positive or negative regulator of expression for target genes involved in organism development.
Descriptor ID |
D000074008
|
MeSH Number(s) |
D12.776.260.534 D12.776.624.664.700.129 D12.776.930.419
|
Concept/Terms |
MDS1 and EVI1 Complex Locus Protein- MDS1 and EVI1 Complex Locus Protein
- Ecotropic Virus Integration Site 1 Protein Homolog
- Zinc Finger Protein Evi1
- MECOM Protein
- Myelodysplasia Syndrome-Associated Protein 1
- Myelodysplasia Syndrome Associated Protein 1
|
Below are MeSH descriptors whose meaning is more general than "MDS1 and EVI1 Complex Locus Protein".
Below are MeSH descriptors whose meaning is more specific than "MDS1 and EVI1 Complex Locus Protein".
This graph shows the total number of publications written about "MDS1 and EVI1 Complex Locus Protein" by people in this website by year, and whether "MDS1 and EVI1 Complex Locus Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2010 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MDS1 and EVI1 Complex Locus Protein" by people in Profiles.
-
Evi1 governs Kdm6b-mediated histone demethylation to regulate the Laptm4b-driven mTOR pathway in hematopoietic progenitor cells. J Clin Invest. 2024 Dec 16; 134(24).
-
Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation. Genes Chromosomes Cancer. 2022 02; 61(2):71-80.
-
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 05 11; 36(19):2737-2749.
-
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):11511-6.
-
Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. Proc Natl Acad Sci U S A. 2013 Apr 02; 110(14):5594-9.
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14; 18(6):553-67.
-
EVI1 abrogates interferon-alpha response by selectively blocking PML induction. J Biol Chem. 2005 Jan 07; 280(1):428-36.
-
Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. Leukemia. 1997 Apr; 11 Suppl 3:273-8.
-
The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia. 1997 Mar; 11(3):352-8.
-
Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A. 1996 Feb 20; 93(4):1642-7.